Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus lenalidomide and dexamethasone in newly diagnosed t(11;14)-positive multiple myeloma in patients ineligible for high-dose therapy
2018-003287-31Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by AbbVie Inc. Primary endpoint: Complete response or better. Started Jun 2019; status: terminated.
02
Drugs
venetoclaxlenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-003287-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003287-31.